DEBx Medical ist bereit für ein beschleunigtes Wachstum im Bereich der Lösungen für chronische Wunden, gestützt durch die zweite Investitionsrunde von TVM Capital Healthcare.
AMSTERDAM und DUBAI, [...] Read more »
DEBx Medical obtient de nouveaux investissements auprès de TVM Capital Healthcare
Grâce au deuxième tour d’investissement de TVM Capital Healthcare, DEBx Medical s’apprête à accélérer sa croissance dans le domaine des solutions de traitement des plaies [...] Read more »
A DEBx Medical garante investimento expandido da TVM Capital Healthcare
A DEBx Medical está preparada para um crescimento acelerado em soluções para feridas crônicas, com o apoio da segunda rodada de investimento da TVM Capital Healthcare.
AMSTERDÃ e DUBAI, [...] Read more »
DEBx Medical Secures Expanded Investment from TVM Capital Healthcare
DEBx Medical is poised for accelerated growth in chronic wound solutions, bolstered by the second round of investment by TVM Capital Healthcare.
AMSTERDAM and DUBAI, United Arab Emirates, Nov. 13, 2024 [...] Read more »
Angelini Pharma Enters Into An Exclusive Option Agreement With Cureverse to License Global Development and Commercialization Rights For A Novel and Innovative Clinical-Stage Brain Health Asset
- The agreement gives Angelini Pharma an option to exclusive licensing rights to develop and commercialize CV–011, a clinical Phase 1 investigational novel compound with broad [...] Read more »
Curium Announces Strategic Partnership with PeptiDream for Prostate Cancer Theranostics in Japan
- Collaboration to include the clinical development, regulatory filing, and commercialization in Japan of 177Lu–PSMA–I&T and 64Cu–PSMA–I&T
- Builds on long–standing [...] Read more »
A new report from the Access to Medicine Foundation reveals how patient-focused pharma companies' access efforts are
AMSTERDAM, Sept. 10, 2024 (GLOBE NEWSWIRE) — The latest report from the Access to Medicine Foundation takes a first–ever look at the critical issue of how some of the largest pharmaceutical companies are reaching [...] Read more »
Neuer Bericht der Access to Medicine Foundation zeigt Einsatz von Pharmaunternehmen für einen besseren Zugang zu Medikamenten für Patienten
AMSTERDAM, Sept. 10, 2024 (GLOBE NEWSWIRE) — Der neueste Bericht der Access to Medicine Foundation wirft erstmals einen Blick auf die entscheidende Frage, wie einige der größten Pharmaunternehmen Patienten weltweit [...] Read more »
Un nouveau rapport de l’Access to Medicine Foundation révèle à quel point les efforts des entreprises pharmaceutiques en matière d’accès aux médicaments sont axés sur les patients
AMSTERDAM, 10 sept. 2024 (GLOBE NEWSWIRE) — Le dernier rapport de l’Access to Medicine Foundation se penche pour la première fois sur la question cruciale de l’approche de certaines des plus grandes entreprises [...] Read more »
Um novo relatório da “Access to Medicine Foundation” revela como os esforços de acesso das empresas farmacêuticas estão centrados nos pacientes
AMESTERDÃO, Sept. 10, 2024 (GLOBE NEWSWIRE) — O mais recente relatório da Access to Medicine Foundation analisa, pela primeira vez, a questão crítica de como algumas das maiores empresas farmacêuticas [...] Read more »
TaiMed Biologics تبرم شراكة تعاون مع AcedrA BioPharmaceuticals لتسويق عقارTrogarzo® (Ibalizumab-uiyk) في منطقة الشرق الأوسط وشمال أفريقيا
تايبيه، تايوان والرياض، المملكة [...] Read more »
TaiMed Biologics and AcedrA BioPharmaceuticals Partner to Commercialize Trogarzo® (Ibalizumab-uiyk) in the Middle East and North Africa Region
TAIPEI, Taiwan and RIYADH, Saudi Arabia, March 18, 2024 (GLOBE NEWSWIRE) — Taimed Biologics (“TaiMed”), a publicly held Taiwanese biotechnology company, signed an Exclusive License and Distribution [...] Read more »
Ayala Pharmaceuticals Announces Closing of Merger with Biosight
REHOVOT, Israel & MONMOUTH JUNCTION, N.J., Oct. 19, 2023 (GLOBE NEWSWIRE) — Ayala Pharmaceuticals, Inc. (OTCQX: ADXS), a clinical–stage oncology company, today announced the closing of its merger with Biosight, [...] Read more »
NRx Pharmaceuticals, Lotus Pharmaceuticals e Alvogen Inc. anunciam colaboração para desenvolver e comercializar o NRX-101
- NRx Pharmaceuticals, Lotus Pharmaceuticals e Alvogen iro colaborar no desenvolvimento e comercializao futuros de NRX–101 para tratar [...] Read more »
NRx Pharmaceuticals, Lotus Pharmaceuticals und Alvogen Inc. kündigen Zusammenarbeit zur Entwicklung und Vermarktung von NRX-101 an
- NRx Pharmaceuticals, Lotus Pharmaceuticals und Alvogen kooperieren bei der weiteren Entwicklung und Vermarktung von NRX–101 gegen [...] Read more »